Good week for access to affordable medicines

Bracing for another delay – open innovation at the WHO?


EU Policy Opportunities in Biomedical Innovation and the Public Good

Statement on Medicines Patent Pool

Public Event on EU-MERCOSUR in Buenos Aires

The Diagnosis of Childhood Bipolar Disease has led to Catastrophic Consequences

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

Statement on conflicts of interest delivered at WHA on behalf of HAI, Berne Declaration, KEI, TWN, PHM, IBFAN

Conflicts of Interest and the Future of Financing for WHO.

DG Trade public hearing on the “Protection and enforcement of IPR in third countries

EU-Mercosur Trade Negotiations: What Fate for Access to medicines?

Foundations: Conlicts of interests and Democracy issues

European drug regulator challenged over revolving door case involving former Director

Corporate funding linked to EU patient & consumer groups policy


EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

ACTA, Democracy & Access to Medicines

Selling Sickness through unbranded disease awareness campaigns?

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

Systematic review of drug promotion's influence on prescribing

Doha Declaration Par 6 to be reviewed in TRIPS Council

Welfare Implications of Intellectual Property Enforcement

Dutch Minister of Health supports HAI E's financial transparency recommendations to EMA

Report exposes how Big Pharma has hijacked EU-India trade deal

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

Open Health Forum: more room for civil society?

Priorities of the Belgian Presidency

HAI Europe recommendations for improved conflict of interest declarations at EMA